Jonathan H. Rayment

1.5k total citations · 1 hit paper
39 papers, 600 citations indexed

About

Jonathan H. Rayment is a scholar working on Pulmonary and Respiratory Medicine, Atomic and Molecular Physics, and Optics and Surgery. According to data from OpenAlex, Jonathan H. Rayment has authored 39 papers receiving a total of 600 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 11 papers in Atomic and Molecular Physics, and Optics and 10 papers in Surgery. Recurrent topics in Jonathan H. Rayment's work include Cystic Fibrosis Research Advances (15 papers), Neonatal Respiratory Health Research (14 papers) and Atomic and Subatomic Physics Research (11 papers). Jonathan H. Rayment is often cited by papers focused on Cystic Fibrosis Research Advances (15 papers), Neonatal Respiratory Health Research (14 papers) and Atomic and Subatomic Physics Research (11 papers). Jonathan H. Rayment collaborates with scholars based in Canada, United States and Australia. Jonathan H. Rayment's co-authors include Félix Ratjen, Marcus J. Couch, Giles Santyr, Nikhil Kanhere, William J. Muller, Donald E. White, Sanja Stanojevic, George Retsch‐Bogart, Felipe Morgado and David Manson and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Jonathan H. Rayment

36 papers receiving 591 citations

Hit Papers

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaft... 2023 2026 2024 2025 2023 20 40 60
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
    2023 74 citations Jennifer L. Goralski, Jordana E. Hoppe et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan H. Rayment Canada 14 387 149 87 70 59 39 600
Long-Hai Zhao United States 12 180 0.5× 61 0.4× 46 0.5× 117 1.7× 82 1.4× 14 553
Rafael Firszt United States 12 95 0.2× 121 0.8× 178 2.0× 65 0.9× 82 1.4× 21 532
James Eaden United Kingdom 8 109 0.3× 111 0.7× 59 0.7× 57 0.8× 43 0.7× 20 275
C. Towe United States 13 203 0.5× 49 0.3× 195 2.2× 31 0.4× 13 0.2× 40 462
Hsiang‐Hung Shih Taiwan 12 106 0.3× 25 0.2× 204 2.3× 245 3.5× 57 1.0× 27 715
Daniel R. Mazori United States 10 111 0.3× 28 0.2× 43 0.5× 93 1.3× 8 0.1× 44 439
Richard A. Guyer United States 13 54 0.1× 32 0.2× 211 2.4× 27 0.4× 23 0.4× 34 529
Matthew S. Fox Canada 16 85 0.2× 300 2.0× 51 0.6× 331 4.7× 213 3.6× 36 562
Sabine Wege Germany 9 376 1.0× 50 0.3× 29 0.3× 33 0.5× 4 0.1× 22 462
Jian-Yu Rao United States 8 46 0.1× 130 0.9× 53 0.6× 20 0.3× 10 0.2× 10 578

Countries citing papers authored by Jonathan H. Rayment

Since Specialization
Citations

This map shows the geographic impact of Jonathan H. Rayment's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan H. Rayment with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan H. Rayment more than expected).

Fields of papers citing papers by Jonathan H. Rayment

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan H. Rayment. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan H. Rayment. The network helps show where Jonathan H. Rayment may publish in the future.

Co-authorship network of co-authors of Jonathan H. Rayment

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan H. Rayment. A scholar is included among the top collaborators of Jonathan H. Rayment based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan H. Rayment. Jonathan H. Rayment is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bell, Laura C., Jeffrey N. Bone, Bastiaan Driehuys, et al.. (2025). A Systematic Review of the Variability of Ventilation Defect Percent Generated From Hyperpolarized Noble Gas Pulmonary Magnetic Resonance Imaging. Journal of Magnetic Resonance Imaging. 62(3). 625–639.
3.
Wainwright, Claire, Susanna A. McColley, Paul McNally, et al.. (2025). Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. American Journal of Respiratory and Critical Care Medicine. 211(10). 1915–1925. 1 indexed citations
4.
Rayment, Jonathan H., et al.. (2024). XE-ing the Difference: Variability of Xenon MRI in Children With Primary Ciliary Dyskinesia. A5163–A5163. 1 indexed citations
5.
Tobia, Antonino, et al.. (2024). Trametinib and Lymphangiectasia in Noonan Syndrome: A Success Story. A2282–A2282.
6.
Waters, Valerie, Michelle Shaw, Lucy Perrem, et al.. (2024). A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment. European Respiratory Journal. 63(6). 2302278–2302278. 5 indexed citations
7.
Rayment, Jonathan H., et al.. (2023). Multiple breath washout and oscillometry after allogenic HSCT: a scoping review. European Respiratory Review. 32(169). 220251–220251. 4 indexed citations
8.
Goralski, Jennifer L., Jordana E. Hoppe, Marcus Mall, et al.. (2023). Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele. American Journal of Respiratory and Critical Care Medicine. 208(1). 59–67. 74 indexed citations breakdown →
9.
Lavoie, Pascal M. & Jonathan H. Rayment. (2023). Genetics of bronchopulmonary dysplasia: An update. Seminars in Perinatology. 47(6). 151811–151811. 12 indexed citations
10.
Wainwright, Claire, Susanna A. McColley, Paul McNally, et al.. (2023). Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 208(1). 68–78. 34 indexed citations
11.
12.
Rayment, Jonathan H., Fadi Asfour, Margaret Rosenfeld, et al.. (2022). A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR. American Journal of Respiratory and Critical Care Medicine. 206(10). 1239–1247. 20 indexed citations
13.
Liu, Alice, et al.. (2022). Tracheal inflammatory myofibroblastic tumor presenting as an obstructive pediatric foreign body. SHILAP Revista de lepidopterología. 10(12). e6583–e6583. 1 indexed citations
14.
Carlens, Julia, Andrew Bush, Diane M. Renz, et al.. (2022). Heterogenous Disease Course and Long-Term Outcome of Children’s Interstitial Lung Disease Related to Filamin A Gene Variants. Annals of the American Thoracic Society. 19(12). 2021–2030. 10 indexed citations
15.
Rayment, Jonathan H., et al.. (2021). CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis. Journal of Cystic Fibrosis. 21(4). 600–602. 29 indexed citations
16.
Perrem, Lucy, Jonathan H. Rayment, & Félix Ratjen. (2018). The lung clearance index as a monitoring tool in cystic fibrosis. Current Opinion in Pulmonary Medicine. 24(6). 579–585. 19 indexed citations
17.
Santyr, Giles, Nikhil Kanhere, Felipe Morgado, et al.. (2018). Hyperpolarized Gas Magnetic Resonance Imaging of Pediatric Cystic Fibrosis Lung Disease. Academic Radiology. 26(3). 344–354. 45 indexed citations
18.
Rayment, Jonathan H., et al.. (2017). Correcting for tissue nitrogen excretion in multiple breath washout measurements. PLoS ONE. 12(10). e0185553–e0185553. 22 indexed citations
19.
Pontier, Stéphanie M., Laurent Huck, Donald E. White, et al.. (2010). Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene. 29(23). 3374–3385. 39 indexed citations
20.
Rayment, Jonathan H., et al.. (2010). Impact of the Sentinel Node Frozen Section Result on the Probability of Additional Nodal Metastases as Predicted by the MSKCC Nomogram in Breast Cancer. Japanese Journal of Clinical Oncology. 41(3). 314–319. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Long-Hai Zhao Breakdown of academic impact, for papers by Rafael Firszt Breakdown of academic impact, for papers by James Eaden Breakdown of academic impact, for papers by C. Towe Breakdown of academic impact, for papers by Hsiang‐Hung Shih Breakdown of academic impact, for papers by Daniel R. Mazori Breakdown of academic impact, for papers by Richard A. Guyer Breakdown of academic impact, for papers by Matthew S. Fox Breakdown of academic impact, for papers by Sabine Wege Breakdown of academic impact, for papers by Jian-Yu Rao
Rankless by CCL
2026